Gastroparesis Drug Market Report Scope & Overview:

The Gastroparesis Drug Market size is valued at USD 5.11 Billion in 2025 and is projected to reach USD 8.22 Billion by 2035, growing at a CAGR of 4.90% during the forecast period 2025–2035.

The Gastroparesis Drug Market analysis report looks at market demands, clinical applications, and advances in treatments for disorders with delayed gastric emptying, owing to growing numbers of diabetes, gastrointestinal problems, unsolved medical issues, and innovations in medicines. The study covers the period between 2025 to 2035.

Gastroparesis drug adoption surpassed 60 million patients in 2025, driven by rising diabetes, gastrointestinal disorders, and unmet treatment needs.

Market Size and Forecast:

• Market Size in 2025: USD 5.11 Billion

• Market Size by 2035: USD 8.22 Billion

• CAGR: 4.90% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Gastroparesis Drug Market - Request Free Sample Report

Gastroparesis Drug Market Trends:

• Rising prevalence of diabetes and gastrointestinal disorders is increasing the incidence of gastroparesis, driving demand for effective pharmacological treatments.

• Growing unmet need for improved symptom control is accelerating adoption of novel prokinetic, antiemetic, and receptor-targeted therapies.

• Advancements in drug development, including targeted receptor agonists and improved formulations, are enhancing treatment efficacy and patient outcomes.

• Increasing awareness and diagnosis rates of gastroparesis are expanding the treated patient population across healthcare systems.

• Expansion of outpatient care and specialty gastroenterology services is supporting broader access to gastroparesis medications.

• Ongoing clinical research and pipeline therapies are fostering innovation and improving long-term management of chronic gastroparesis cases.

U.S. Gastroparesis Drug Market Insights:

The U.S. Gastroparesis Drug Market is projected to grow from USD 1.68 Billion in 2025 to USD 2.60 Billion by 2035, at a CAGR of 4.46%. Growth is driven by the increasing prevalence of diabetes, rising diagnosis of gastroparesis and increasing access to gastroenterology care, along with ongoing adoption of advanced pharmacological therapies for symptom relief.

Gastroparesis Drug Market Growth Drivers:

• Rising diabetes prevalence and delayed gastric emptying cases driving demand for effective gastroparesis drug therapies.

Increasing incidence of diabetes mellitus and gastrointestinal motility disorders is one of the crucial factors that have a significant influence on the Gastroparesis Drug Market. The rising number of diagnoses and patient education regarding the condition result in early treatment and symptom management, which is expected to contribute to the market. Moreover, an increasing demand for drugs used for the management of symptoms, such as nausea and vomiting, will drive the market ahead.

Over 50% of diagnosed gastroparesis patients are linked to diabetes-related complications in 2025, driving demand for targeted drug therapies.

Gastroparesis Drug Market Restraints:

• Limited treatment options, delayed diagnosis, and adverse drug effects restricting widespread adoption of gastroparesis therapies.

Availability issues with FDA-approved therapies, late diagnosis, or under-diagnosis of the disease, and potential adverse reactions from currently prescribed medicines, are some of the major restraint factors that are adversely impacting the Gastroparesis Drug Market. Due to fluctuating symptoms, patients tend not to adhere to therapy, which, coupled with the difficult nature of the disease, restricts treatment success. The safety and efficacy concerns associated with drugs also impede their uptake despite an increasing demand for better therapeutic options.

Gastroparesis Drug Market Opportunities:

• Growing development of targeted prokinetic and receptor-specific therapies creating opportunities for improved gastroparesis treatment outcomes.

The increased development of prokinetic and receptor-based drugs offers a great chance for the Gastroparesis Drug Market. Many pharmaceutical companies are investing their efforts to develop drugs that can efficiently treat gastroparesis. In this way, many new drugs have been developed to improve gastric emptying and its related complications. Such developments not only help physicians provide a better approach toward treatment but also make treatments more personalized according to the condition of the patient.

Over 30% of gastroparesis clinical trials in 2025 are focused on targeted prokinetic and receptor-specific therapies to improve treatment efficacy.

Gastroparesis Drug Market Segmentation Analysis:

• By Drug Class, Prokinetic Agents held the largest market share of 34.78% in 2025, while Ghrelin Agonists are expected to grow at the fastest CAGR of 6.43% during 2026–2035.

• By Disease Type, Diabetic Gastroparesis dominated with a 52.16% market share in 2025, whereas Idiopathic Gastroparesis is projected to register the fastest CAGR of 5.27% through 2026–2035.

• By Route of Administration, Oral held the largest share of 61.89% in 2025, while Injectable is anticipated to grow at the fastest CAGR of 5.91% during the forecast period.

• By Distribution Channel, Hospital Pharmacies accounted for the highest market share of 46.32% in 2025, whereas Online Pharmacies are expected to expand at the fastest CAGR of 6.08% through 2026–2035.

By Drug Class, Prokinetic Agents Dominate While Ghrelin Agonists Are Fastest Growing:

Prokinetic Agents segment dominated the market owing to high usage of prokinetics agents in clinical practice for enhancing gastric motility and symptom control including delayed gastric emptying, nausea and bloating. Prokinetic-based treatments represented more than 20 million patients within this population in 2025.

Ghrelin Agonists are the fastest-growing segment, whose growth arises from its novel mechanism of stimulating appetite and gastric motility. Over 5 million patients are sequentially assessed in the clinical environment for novel ghrelin-targeted interventions.

By Disease Type, Diabetic Gastroparesis Dominates While Idiopathic Gastroparesis Is Fastest Growing:

Diabetic Gastroparesis segment dominated the market as diabetes stands to be key reasons of delayed gastric emptying and large expanding patient pool with requiring pharmacological treatment. More than 30 million cases of gastroparesis in 2025 were linked with diabetes-induced complications, fueling an ever-present demand for treatment.

Idiopathic Gastroparesis is the fastest-growing segment driven by increasing diagnosis rates and provider awareness. Idiopathic cases account for almost 12 million patients, which explains the growing recognition of unexplained gastric motility disorders, and as a result there is more widespread adoption in treatment with continued clinical evaluation.

By Route of Administration, Oral Dominates While Injectable Is Fastest Growing:

Oral segment dominated the market owing to its convenience, non-invasive characteristic and high patient compliance which resultant making this produce the preferred mode for long-term therapy. Oral therapies were used to manage more than 35 million patients in 2025.

Injectable is the fastest-growing segment, primarily used in patients with severe or refractory cases, where rapid symptom relief is needed. More than 10 million patients are treated with injectable formulations, which can be backed up by hospital-care and advances in drug delivery technologies.

By Distribution Channel, Hospital Pharmacies Dominate While Online Pharmacies Are Fastest Growing:

Hospital segment dominated the market due to hospitals being at the center for dispensing prescribed or dispensed medications, particularly those at newly diagnosed or severe stages that require institutional supervision. More than 25 million prescriptions were filled via hospital pharmacy channels in 2025.

Online Pharmacies are the fastest-growing segment, with the digital healthcare adoption and home delivery services. Fifteen million patients already use online platforms to procure medication, aided by the increasing e-pharmacy infrastructure and growing preference for discreet and accessible purchasing methods.

Gastroparesis Drug Market Regional Analysis:

North America Gastroparesis Drug Market Insights:

North America Gastroparesis Drug Market has a major presence in the industry, capturing 38.62% of the market share in 2025. This is attributed to the high prevalence rate of diabetes in the region, along with the established healthcare system. Awareness, early diagnosis, and easy access to specialized gastrointestinal care and prescription drugs make the region favorable for growth in the market. Furthermore, the high uptake rate of new technologies, ongoing research activities, and availability of approved products aid in driving the regional market.

Get Customized Report as per Your Business Requirement - Enquiry Now

U.S. Gastroparesis Drug Market Insights:

The U.S. Gastroparesis Drug Market is driven by the advanced medical system, increased prevalence of diabetes cases, and high clinical awareness. Extensive availability of gastroenterologists, increased diagnoses, and use of medications approved for treatment will boost the demand for drugs. In addition, research activities, advancements in drugs, and positive reimbursement schemes make U.S. the most mature and developed market.

Asia-Pacific Gastroparesis Drug Market Insights:

The Asia-Pacific Gastroparesis Drug Market is the fastest-growing market, with growth estimated at a CAGR of 6.43% during the forecast period of 2025 to 2035. This market will be driven by increasing cases of diabetes, digestive disorders, and health consciousness in countries such as China, India, Japan, and Southeast Asia. Increasing healthcare infrastructure and rising numbers of diagnoses will fuel the demand in the coming years. Moreover, increasing pharmaceutical investments and conducting clinical studies will contribute significantly to the market growth.

China Gastroparesis Drug Market Insights:

The China Gastroparesis Drug Market include the increase in diabetes prevalence, rise in gastrointestinal disorders, and increased awareness about digestive health. The development in healthcare facilities, provision of gastroenterological services, and diagnosis are aiding the market growth. Increased investment in the pharmaceutical industry, developments in research, and advances in therapy are positioning China well in the Asia-Pacific region.

Europe Gastroparesis Drug Market Insights:

The Europe Gastroparesis Drugs Market has been propelled by the existence of highly developed healthcare facilities, stringent regulatory policies, and high levels of awareness regarding digestive diseases in countries such as Germany, France, and the UK. Increasing incidences of diabetes, higher diagnostic frequency, and improved patient accessibility to specialized treatment centers are major drivers for market growth. Moreover, the availability of well-established drug companies, clinical trials, and innovative treatment options help in fueling the market growth.

Germany Gastroparesis Drug Market Insights:

The Germany Gastroparesis Drug Market is one of the most important markets in Europe, driven by an advanced health care system, efficient medical practices, and increased knowledge about gastroenterological conditions. The increase in the incidence of diabetes, higher diagnosis rates, and availability of specialists contribute significantly to the growing market demand.

Latin America Gastroparesis Drug Market Insights:

The Latin America Gastroparesis Drug Market include the increase in incidence rates of diabetes, increase in the cases of gastro-intestinal diseases, and increased awareness about digestive disorders. The factors facilitating growth in the market include the expansion of healthcare facilities, improved diagnosing abilities, and increased services for gastroenterology in Latin America, including Brazil, Mexico, and Argentina.

Middle East and Africa Gastroparesis Drug Market Insights:

The Middle East & Africa Gastroparesis Drug Market is growing, shows positive growth trends attributed to the growing incidences of diabetes, gastrointestinal disorders, and increased consciousness about digestive diseases. The development of the healthcare system in countries such as UAE, Saudi Arabia, and South Africa is positively influencing market dynamics and slow uptake of novel gastroparesis drugs.

Gastroparesis Drug Market Competitive Landscape:

Evoke Pharma is a specialty pharmaceutical company that specializes in developing and commercializing products for gastrointestinal disorders, mainly gastroparesis. The company’s executives are heavily linked to its FDA-approved drug, which aims to address symptoms such as nausea and delayed gastric emptying. Evoke Pharma developed a unique presence by addressing unmet needs in the management of gastroparesis with targeted research, clinical development and physician awareness efforts. The market position is supported by its focused proprietary portfolio, alliances, and continued efforts to promote adoption by gastroenterology clinicians in clinical settings.

• In August 2025, Evoke Pharma continued advancing and commercializing GIMOTI, strengthening its gastroparesis portfolio through extended patent protection, improved physician adoption, and sustained focus on diabetic gastroparesis symptom management, supporting long-term market exclusivity and treatment accessibility.

Vanda is a biopharmaceutical company focused on the development and commercialisation of products for the treatment of central nervous system (CNS) disorders, and gastrointestinal (GI) disorders (e.g., gastroparesis). Utilizing its knowledge of receptor-targeted drug mechanisms and in-house clinical research capabilities, the company aims to address complex medical issues. Vanda occupies a frontier in drug development, commercialization and regulatory approvals. Its market-leading position in the gastroparesis drug landscape is supported by strong IP, existing clinical programs and a precision medicine focus.

• In June 2025, Vanda Pharmaceuticals progressed its tradipitant program for gastroparesis through ongoing regulatory discussions and clinical evaluations, reinforcing its commitment to receptor-targeted therapies while expanding its gastrointestinal pipeline and pursuing potential approvals to strengthen its market position.

Neurogastrx is a clinical-stage biopharmaceutical company developing innovative therapeutics for gastroparesis and related gastrointestinal motility disorders. The next-generation prokinetic and receptor-based therapies for enhanced gastric motility and symptom control are in development by the company. Neurogastrx is making progress by focusing on pipeline innovation clinical trials, and high unmet medical needs. Backed by strong scientific evidence, collaborations, and a well-defined development strategy to deliver improved treatment solutions with favorable efficacy or safety profile, it has made its mark as an attractive emerging contender in the gastroparesis space.

• In November 2025, Neurogastrx advanced its NG101 clinical program, demonstrating progress in addressing nausea and vomiting linked to motility disorders, while continuing pipeline development and clinical trials focused on innovative therapies targeting unmet needs in gastroparesis treatment.

Gastroparesis Drug Market Key Players:

Some of the Gastroparesis Drug Market Companies are: 

• Evoke Pharma

• Vanda Pharmaceuticals

• Neurogastrx

• Processa Pharmaceuticals

• CinDome Pharma

• Renexxion Ireland

• Dr. Falk Pharma GmbH

• AbbVie

• AstraZeneca

• GlaxoSmithKline (GSK)

• Abbott Laboratories

• Bausch Health

• Theravance Biopharma

• Zydus Group

• ANI Pharmaceuticals

• Takeda Pharmaceutical

• Johnson & Johnson

• Pfizer

• Teva Pharmaceutical

• Sun Pharmaceuticals Industries